Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.210
0.00 (0.00%)
Dec 20, 2024, 4:00 PM EST - Market closed
Arbutus Biopharma Revenue
Arbutus Biopharma had revenue of $1.34M in the quarter ending September 30, 2024, a decrease of -71.25%. This brings the company's revenue in the last twelve months to $6.74M, down -69.69% year-over-year. In the year 2023, Arbutus Biopharma had annual revenue of $18.14M, down -53.51%.
Revenue (ttm)
$6.74M
Revenue Growth
-69.69%
P/S Ratio
85.86
Revenue / Employee
$92,356
Employees
73
Market Cap
608.27M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 18.14M | -20.88M | -53.51% |
Dec 31, 2022 | 39.02M | 28.03M | 255.11% |
Dec 31, 2021 | 10.99M | 4.07M | 58.92% |
Dec 31, 2020 | 6.91M | 903.00K | 15.02% |
Dec 31, 2019 | 6.01M | 66.00K | 1.11% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Varex Imaging | 811.00M |
Ironwood Pharmaceuticals | 378.42M |
Pharming Group | 285.75M |
Entrada Therapeutics | 215.23M |
Butterfly Network | 76.22M |
Stoke Therapeutics | 16.74M |
Autolus Therapeutics | 10.09M |
ABUS News
- 18 days ago - Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors - Business Wire
- 25 days ago - Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat - GlobeNewsWire
- 5 weeks ago - Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon - GlobeNewsWire
- 5 weeks ago - Arbutus to Present at Jefferies London Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update - GlobeNewsWire
- 2 months ago - Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024 - GlobeNewsWire
- 3 months ago - Arbutus to Participate in Two Upcoming Investor Conferences - GlobeNewsWire